ArticleOphthalmology2014

Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.

Joshua D Stein et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.